Abstract
AbstractThe emergence of SARS-CoV-2 has had a profound adverse impact on global health and continues to remain a threat worldwide. The disease spectrum of COVID-19 ranges from asymptomatic to fatal clinical outcomes especially in the elderly population and in individuals with underlying medical conditions. The impact of COVID-19 on host immune responses and immune cells at the protein and DNA levels remains largely ambiguous. In a case-control study, here we explored the impact of COVID-19 on DNA methylation patterns in the upper respiratory airway to determine how SARS-CoV-2 infection altered the immune status of individuals requiring hospitalization for COVID-19. We performed DNA methylation arrays on nasopharyngeal swabs at inclusion/hospitalization as well as 6 weeks post-inclusion. Our study reveals a distinct DNA methylation pattern in COVID-19 patients compared to healthy controls, characterized by 317 779 differentially methylated CpGs. Notably, within the transcription start sites and gene body, COVID-19 patients exhibited a higher number of genes/CpGs with elevated methylation levels. Enrichment analysis of methylated genes at transcription start sites highlighted the impact on genes associated with inflammatory responses and immune functions. Some SARS-CoV-2 -induced CpG methylations were transient, returning to normal levels by 6 weeks post-inclusion. Enriched genes of interest included IL-17A, a pivotal cytokine implicated with inflammation and healing, and NUP93, associated with antiviral innate immunity. Further, six genes in our data set, OAS1, CXCR5, APP, CCL20, CNR2, and C3AR1, were found in enrichment analysis with previous COVID-19 studies. Additionally, RNAse1 and RNAse2 emerged as key regulators, while IL-18 played a role in various biological processes in COVID-19 patients. Overall, our results demonstrates that COVID-19 has a major impact on the upper airway by modifying the methylation pattern of many genes and this could have implications for the conditioning of the airways and how the individual response to future airway infections.
Publisher
Cold Spring Harbor Laboratory
Reference85 articles.
1. CDC.. COVID-19 Treatments and Medications. https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html (2023).
2. WHO. WHO Coronavirus (COVID-19) Dashboard.. https://covid19.who.int/ (2020 7 February 2023).
3. McIntosh, K. COVID-19: Clinical features UpToDate 2023 https://www.uptodate.com/contents/covid-19-clinical-features.
4. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations;Lancet Respir Med,2020
5. SARS-CoV-2 variant biology: immune escape, transmission and fitness;Nat Rev Microbiol,2023